Amonafide

Amonafide

Clinical data
Trade names	Xanafide, Quinamed
ATC code	none
Identifiers
IUPAC name 5-amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
CAS Number	69408-81-7
PubChem CID	50515
ChemSpider	45804 Y
UNII	1Q8D39N37L
KEGG	D10090 Y
ChEMBL	ChEMBL428676 Y
CompTox Dashboard (EPA)	DTXSID30219562
Chemical and physical data
Formula	C16H17N3O3
Molar mass	299.330 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
InChI InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3 Y Key:UPALIKSFLSVKIS-UHFFFAOYSA-N Y
(verify)

Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.

It was being developed as an anti-cancer therapy by Antisoma.

As of 2008, it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML). In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.

See also

• Alrestatin

External links

• Amonafide entry in the public domain NCI Dictionary of Cancer Terms
• Clinical trials of amonafide at ClinicalTrials.gov

 This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.